Emerging Therapeutic Strategies to Overcome Drug Resistance in Cancer Cells

Overview

Journal Cancers (Basel)

Publisher MDPI

Specialty Oncology

Date 2024 Jul 13

PMID 39001539

Authors

Pankaj Garg

Jyoti Malhotra

Prakash Kulkarni

David Horne

Ravi Salgia

Sharad S Singhal

Affiliations

Soon will be listed here.

Abstract

The rise of drug resistance in cancer cells presents a formidable challenge in modern oncology, necessitating the exploration of innovative therapeutic strategies. This review investigates the latest advancements in overcoming drug resistance mechanisms employed by cancer cells, focusing on emerging therapeutic modalities. The intricate molecular insights into drug resistance, including genetic mutations, efflux pumps, altered signaling pathways, and microenvironmental influences, are discussed. Furthermore, the promising avenues offered by targeted therapies, combination treatments, immunotherapies, and precision medicine approaches are highlighted. Specifically, the synergistic effects of combining traditional cytotoxic agents with molecularly targeted inhibitors to circumvent resistance pathways are examined. Additionally, the evolving landscape of immunotherapeutic interventions, including immune checkpoint inhibitors and adoptive cell therapies, is explored in terms of bolstering anti-tumor immune responses and overcoming immune evasion mechanisms. Moreover, the significance of biomarker-driven strategies for predicting and monitoring treatment responses is underscored, thereby optimizing therapeutic outcomes. For insights into the future direction of cancer treatment paradigms, the current review focused on prevailing drug resistance challenges and improving patient outcomes, through an integrative analysis of these emerging therapeutic strategies.

Citing Articles

Mechanisms and Strategies to Overcome Drug Resistance in Colorectal Cancer.

Haynes J, Manogaran P Int J Mol Sci. 2025; 26(5).

PMID: 40076613 PMC: 11901061. DOI: 10.3390/ijms26051988.

Metabolic crossroads: unravelling immune cell dynamics in gastrointestinal cancer drug resistance.

Suri C, Pande B, Suhasini Sahithi L, Swarnkar S, Khelkar T, Verma H Cancer Drug Resist. 2025; 8:7.

PMID: 40051496 PMC: 11883236. DOI: 10.20517/cdr.2024.164.

Cancer Vaccines and Beyond: The Transformative Role of Nanotechnology in Immunotherapy.

Delgado-Almenta V, Blaya-Canovas J, Calahorra J, Lopez-Tejada A, Grinan-Lison C, Granados-Principal S Pharmaceutics. 2025; 17(2).

PMID: 40006583 PMC: 11859086. DOI: 10.3390/pharmaceutics17020216.

Microbiome Integrity Enhances the Efficacy and Safety of Anticancer Drug.

Mafe A, Busselberg D Biomedicines. 2025; 13(2).

PMID: 40002835 PMC: 11852609. DOI: 10.3390/biomedicines13020422.

Progress in Drug Delivery Systems Based on Nanoparticles for Improved Glioblastoma Therapy: Addressing Challenges and Investigating Opportunities.

Rahman M, Jalouli M, Yadab M, Al-Zharani M Cancers (Basel). 2025; 17(4).

PMID: 40002294 PMC: 11852615. DOI: 10.3390/cancers17040701.

References

Baylin S, Jones P . Epigenetic Determinants of Cancer. Cold Spring Harb Perspect Biol. 2016; 8(9). PMC: 5008069. DOI: 10.1101/cshperspect.a019505. View

Islam S, Walker R . Advanced imaging (positron emission tomography and magnetic resonance imaging) and image-guided biopsy in initial staging and monitoring of therapy of lung cancer. Cancer J. 2013; 19(3):208-16. PMC: 4834561. DOI: 10.1097/PPO.0b013e318295185f. View

Min H, Lee H . Molecular targeted therapy for anticancer treatment. Exp Mol Med. 2022; 54(10):1670-1694. PMC: 9636149. DOI: 10.1038/s12276-022-00864-3. View

Lin B, Du L, Li H, Zhu X, Cui L, Li X . Tumor-infiltrating lymphocytes: Warriors fight against tumors powerfully. Biomed Pharmacother. 2020; 132:110873. DOI: 10.1016/j.biopha.2020.110873. View

Sordo-Bahamonde C, Lorenzo-Herrero S, Gonzalez-Rodriguez A, Martinez-Perez A, Rodrigo J, Garcia-Pedrero J . Chemo-Immunotherapy: A New Trend in Cancer Treatment. Cancers (Basel). 2023; 15(11). PMC: 10252089. DOI: 10.3390/cancers15112912. View

Yan Y, Kumar A, Finnes H, Markovic S, Park S, Dronca R . Combining Immune Checkpoint Inhibitors With Conventional Cancer Therapy. Front Immunol. 2018; 9:1739. PMC: 6072836. DOI: 10.3389/fimmu.2018.01739. View

Yang F, Wang J, Wang Y, Liu B, Molina J . Comparative Analysis of Predictive Biomarkers for PD-1/PD-L1 Inhibitors in Cancers: Developments and Challenges. Cancers (Basel). 2022; 14(1). PMC: 8750062. DOI: 10.3390/cancers14010109. View

Qian S, Wei Z, Yang W, Huang J, Yang Y, Wang J . The role of BCL-2 family proteins in regulating apoptosis and cancer therapy. Front Oncol. 2022; 12:985363. PMC: 9597512. DOI: 10.3389/fonc.2022.985363. View

Mansoori B, Mohammadi A, Davudian S, Shirjang S, Baradaran B . The Different Mechanisms of Cancer Drug Resistance: A Brief Review. Adv Pharm Bull. 2017; 7(3):339-348. PMC: 5651054. DOI: 10.15171/apb.2017.041. View

10.

Zafar A, Khan M, Abu J, Naeem A . Revolutionizing cancer care strategies: immunotherapy, gene therapy, and molecular targeted therapy. Mol Biol Rep. 2024; 51(1):219. PMC: 10822809. DOI: 10.1007/s11033-023-09096-8. View

11.

Mir S, Hamid L, Bader G, Shoaib A, Rahamathulla M, Alshahrani M . Role of Nanotechnology in Overcoming the Multidrug Resistance in Cancer Therapy: A Review. Molecules. 2022; 27(19). PMC: 9571152. DOI: 10.3390/molecules27196608. View

12.

Sadida H, Abdulla A, Al Marzooqi S, Hashem S, Macha M, Akil A . Epigenetic modifications: Key players in cancer heterogeneity and drug resistance. Transl Oncol. 2023; 39:101821. PMC: 10654239. DOI: 10.1016/j.tranon.2023.101821. View

13.

Al-Tabba A, Al-Hussaini M, Mansour R, Sultan H, Abdel-Razeq H, Mansour A . Ethical Considerations for Treating Cancer Patients During the SARS-CoV-2 Virus Crisis: To Treat or Not to Treat? A Literature Review and Perspective From a Cancer Center in Low-Middle Income Country. Front Med (Lausanne). 2020; 7:561168. PMC: 7580805. DOI: 10.3389/fmed.2020.561168. View

14.

Passaro A, Al Bakir M, Hamilton E, Diehn M, Andre F, Roy-Chowdhuri S . Cancer biomarkers: Emerging trends and clinical implications for personalized treatment. Cell. 2024; 187(7):1617-1635. PMC: 7616034. DOI: 10.1016/j.cell.2024.02.041. View

15.

Helleday T . The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings. Mol Oncol. 2011; 5(4):387-93. PMC: 5528309. DOI: 10.1016/j.molonc.2011.07.001. View

16.

Siddiqui M, Rajkumar S . The high cost of cancer drugs and what we can do about it. Mayo Clin Proc. 2012; 87(10):935-43. PMC: 3538397. DOI: 10.1016/j.mayocp.2012.07.007. View

17.

Pang Z, Lu M, Zhang Y, Gao Y, Bai J, Gu J . Neoantigen-targeted TCR-engineered T cell immunotherapy: current advances and challenges. Biomark Res. 2023; 11(1):104. PMC: 10690996. DOI: 10.1186/s40364-023-00534-0. View

18.

Masuda H, Zhang D, Bartholomeusz C, Doihara H, Hortobagyi G, Ueno N . Role of epidermal growth factor receptor in breast cancer. Breast Cancer Res Treat. 2012; 136(2):331-45. PMC: 3832208. DOI: 10.1007/s10549-012-2289-9. View

19.

Hofman P . Next-Generation Sequencing with Liquid Biopsies from Treatment-Naïve Non-Small Cell Lung Carcinoma Patients. Cancers (Basel). 2021; 13(9). PMC: 8122958. DOI: 10.3390/cancers13092049. View

20.

Gonzalez H, Hagerling C, Werb Z . Roles of the immune system in cancer: from tumor initiation to metastatic progression. Genes Dev. 2018; 32(19-20):1267-1284. PMC: 6169832. DOI: 10.1101/gad.314617.118. View